$IONS Cashflow Statement | Understand Stock

$IONS

$43.96 +$0.54 (1.24%) Close

$IONS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of right-of-use operating lease assets
Amortization of other assets
Amortization of discount on investments, net
Amortization of debt issuance costs
Non-cash royalty revenue related to sale of royalties
Non-cash interest related to sale of future royalties
Stock-based compensation expense
Gain on early retirement of debt
Inducement expense related to early retirement of debt
Non-cash losses (gains) related to disposal of property, plant and equipment
Loss (gain) on sale of real estate assets
Loss (gain) on investments, net
Deferred income taxes, including changes in valuation allowance
Non-cash losses related to other assets
Changes in operating assets and liabilities:
Contracts receivable
Inventories
Other current and long-term assets
Long-term income taxes receivable (payable)
Accounts payable
Income taxes
Accrued compensation
Accrued liabilities and other liabilities
Deferred contract revenue
Net cash used in operating activities

Investing activities:
Purchases of short-term investments
Proceeds from sale of short-term investments
Purchases of property, plant and equipment
Proceeds from sale of real estate assets
Acquisition of licenses and other assets, net
Purchases of strategic investments
Net cash used in investing activities
Financing activities:
Proceeds from issuance of common stock through equity plans, net
Proceeds from issuance of common stock in public offering, net
Proceeds from issuance of convertible senior notes
1.75 Percent Convertible Senior Notes
0.125 Percent Convertible Senior Notes
0 Percent Convertible Senior Notes
0% Notes due 2030
1.75% Notes due 2028
Convertible Senior Notes Due 2026
Total proceeds from issuance of convertible senior notes

Convertible senior notes issuance costs
1.75 Percent Convertible Senior Notes
0.125 Percent Convertible Senior Notes
0 Percent Convertible Senior Notes
0% Notes due 2030
1.75% Notes due 2028
Total convertible senior notes issuance costs

Proceeds from sale of future royalties
Payments of transaction costs related to sale of future royalties
Proceeds from real estate transaction
Principal payments on mortgage debt
Purchase of noncontrolling interest of Akcea Therapeutics, Inc., including cash payments for cancellation of Akcea Therapeutics, Inc. equity awards
Principal payments on line of credit
Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options
Net cash provided by financing activities
Effects of exchange rates on cash
Repurchase of $200 million principal amount of 0 percent convertible senior notes due 2026
0.125 Percent Convertible Senior Notes
1 Percent Convertible Senior Notes
Total repurchase of $200 million principal amount of 0 percent convertible senior notes due 2026
Repayment of 0.125 percent convertible senior notes due 2024
0.125 Percent Convertible Senior Notes
1 Percent Convertible Senior Notes
Total repayment of 0.125 percent convertible senior notes due 2024

Proceeds from issuance of warrants
0 Percent Convertible Senior Notes
Convertible Senior Notes Due 2026
Total proceeds from issuance of warrants

Purchase of note hedges
0 Percent Convertible Senior Notes
Convertible Senior Notes Due 2026
Total purchase of note hedges

Repurchases and retirements of common stock

Effects of exchange rates on cash
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosures of cash flow information:
Interest paid
Income taxes paid (refunds received), net
Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations
0.125 percent convertible senior notes principal issued related to our December 2019 debt exchange/issuance
1 percent convertible senior notes principal extinguished related to our December 2019 debt exchange
Amounts accrued for capital and patent expenditures
Inducement related to repurchase of 0 percent convertible senior notes due 2026

Comments